

# Mark D Long

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7717462/publications.pdf>

Version: 2024-02-01

38  
papers

1,079  
citations

471061

17  
h-index

454577

30  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1431  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. <i>Biomolecules</i> , 2017, 7, 15.	1.8	92
2	MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. <i>Nature Communications</i> , 2020, 11, 338.	5.8	87
3	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. <i>Nature Communications</i> , 2020, 11, 5415.	5.8	85
4	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. <i>Oncotarget</i> , 2014, 5, 824-840.	0.8	52
5	Activation of NF- $\kappa$ B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	47
6	MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. <i>Cancer Research</i> , 2021, 81, 1111-1122.	0.4	46
7	The miR-96 and RAR $\beta$ signaling axis governs androgen signaling and prostate cancer progression. <i>Oncogene</i> , 2019, 38, 421-444.	2.6	45
8	MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2019, 79, 5711-5722.	0.4	45
9	MUC1-C integrates activation of the IFN- $\beta$ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. , 2021, 9, e002115.		41
10	MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. <i>Oncogene</i> , 2021, 40, 4930-4940.	2.6	41
11	Pan-Cancer Analyses of the Nuclear Receptor Superfamily. <i>Nuclear Receptor Research</i> , 2015, 2, .	2.5	40
12	Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. <i>Nature Communications</i> , 2020, 11, 52.	5.8	37
13	MUC1-C drives stemness in progression of colitis to colorectal cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	36
14	Vitamin D Receptor and RXR in the Post-Genomic Era. <i>Journal of Cellular Physiology</i> , 2015, 230, 758-766.	2.0	35
15	Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF- $\kappa$ B binding that is linked to immune phenotypes. <i>BMC Genomics</i> , 2017, 18, 132.	1.2	35
16	Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4682-4696.	3.9	35
17	CD8 <sup>+</sup> T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	24
18	Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. <i>Nucleic Acids Research</i> , 2015, 43, 7330-7348.	6.5	22

#	ARTICLE	IF	CITATIONS
19	Cooperative behavior of the nuclear receptor superfamily and its deregulation in prostate cancer. <i>Carcinogenesis</i> , 2014, 35, 262-271.	1.3	19
20	Identification of transcription factor co-regulators that drive prostate cancer progression. <i>Scientific Reports</i> , 2020, 10, 20332.	1.6	19
21	Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. <i>Cell Reports</i> , 2021, 37, 110109.	2.9	19
22	MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. <i>Oncogene</i> , 2019, 38, 7266-7277.	2.6	17
23	MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2022, 20, 556-567.	1.5	17
24	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. <i>Oncoimmunology</i> , 2022, 11, 2029298.	2.1	17
25	Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 130-138.	1.2	14
26	miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 212-229.	3.0	14
27	Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling. , 2022, 10, e003827.		14
28	Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2580.	1.7	14
29	Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. <i>Oncotarget</i> , 2017, 8, 103758-103774.	0.8	13
30	Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. <i>International Journal of Cancer</i> , 2020, 146, 2147-2155.	2.3	12
31	Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 38-50.	2.0	9
32	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1379-1390.	1.5	8
33	Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8 + T Cell Responses. <i>Advanced Science</i> , 2021, , 2103023.	5.6	5
34	An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity. <i>Cancer Immunology Research</i> , 2022, 10, 314-326.	1.6	5
35	Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 11405.	1.6	3
36	Concurrent Aspirin Use Is Associated with Improved Outcome in Rectal Cancer Patients Who Undergo Chemoradiation Therapy. <i>Cancers</i> , 2021, 13, 205.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy. <i>Cytotherapy</i> , 2022, 24, 802-817.	0.3	2
38	Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers. <i>Cancers</i> , 2022, 14, 2350.	1.7	1